Clinical trial
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
NCT00253630 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00253630 |
|---|---|
| Title | Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Indolent Non-Hodgkin's Lymphoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma |
| Intervention type | Drug, Other |
| Interventions | Laboratory Biomarker Analysis, Vorinostat |
| Enrollment | 37 |
| Start date | Sep 1, 2005 |
| Primary completion | May 1, 2016 |
| Completion | May 1, 2016 |
| First posted | Nov 15, 2005 |
| Last update posted | Mar 6, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: